Abstract:BACKGROUND:IgA nephropathy (IgAN) is the most common glomerulonephritis with various histologic and clinical phenotypes. The mechanisms underlying the pathogenesis of IgAN remained unclear. But now altered O-glycosylation of serum IgA1 observed in these patients was considered to be a key contributory factor. The aim of the current study is to investigate whether aberrantly glycosylated IgA1 was associated with pathologic phenotypes of IgAN.METHODS:Sera from 107 patients with IgAN recently diagnosed were collected. Fifty patients were with mild mesangial proliferative IgAN, the others were with focal proliferative and sclerosing IgAN. Sera from 22 normal blood donors were used as normal controls. Biotinylated lectins were used in enzyme-linked immunosorbent assay (ELISA) to examine different glycans on IgA1 molecules. The alpha2,6 sialic acid was detected by elderberry bark lectin (SNA), the exposure of terminal galactose (Gal) and N-acetylgalactosamine (GalNAc) were detected by arachis hypogaea [peanut agglutinin (PNA)] and vilsa villosa lectin (VVL), respectively. The serum IgA1 glycans levels corrected by serum IgA1 concentrations were compared between patients and controls.RESULTS:Reduced terminal alpha2,6 sialic acid (1.16 +/- 0.21 vs. 0.98 +/- 0.31) (P= 0.008) and galactosylation (0.30 +/- 0.29 vs. 0.16 +/- 0.19) (P= 0.029) increased exposure of (GalNAc) (0.00 vs. 0.03) (P= 0.024) were demonstrated in serum IgA1 from patients with IgAN as compared with those in controls. More important, the exposures of 2,6 sialic acid and Gal were significantly decreased, especially in patients with focal proliferative and sclerosing IgAN compared with that in patients with mild mesangial proliferative IgAN (0.91 +/- 0.34 vs. 1.05 +/- 0.25) (P= 0.014) (0.108 +/- 0.137 vs. 0.221 +/- 0.219) (P= 0.018). However, no significant difference was found between patients with mild mesangial proliferative IgAN and normal controls (P > 0.05). The exposure of GalNAc of serum IgA1 from patients with focal proliferative and sclerosing IgAN was significantly higher than that of controls (P= 0.017), but had no statistical difference with that of patients with mild mesangial proliferative IgAN.CONCLUSION:The desialylation and degalactosylation of IgA1 in sera of patients with IgAN were closely associated with pathologic phenotypes.

Advances in IgA Glycosylation and Its Correlation with Diseases

The glycosylation of immunoglobulin G and its alterations in diseases

Sialylated immunoglobulin G: a promising diagnostic and therapeutic strategy for autoimmune diseases

Recent advances in the molecular understanding of immunoglobulin A

Immunoglobulin G glycosylation and its alterations in aging-related diseases

The Effects of Glycosylation on the Structure and Functional Properties of IgG/IgY

Effects of N-glycans on the structure of human IgA2

Cytokines in the Immune Microenvironment Change the Glycosylation of IgG by Regulating Intracellular Glycosyltransferases

Understanding the role of antibody glycosylation through the lens of severe viral and bacterial diseases

The Glycans Deficiencies Of Macromolecular Iga1 Is A Contributory Factor Of Variable Pathological Phenotypes Of Iga Nephropathy

Pathogenic role of glycan-specific IgG antibodies in IgA nephropathy

Immunoglobulin Glycosylation Effects in Allergy and Immunity

IgG N-glycans

The role of N-glycosylation in B-cell biology and IgG activity. The aspects of autoimmunity and anti-inflammatory therapy

Aberrant glycosylation of IgA1 and anti-glycan antibodies in IgA nephropathy: role of mucosal immune system

Self-Aggregated Deglycosylated Iga1 With Or Without Igg Were Associated With The Development Of Iga Nephropathy

IgA displays site- and subclass-specific glycoform differences despite equal glycoenzyme expression

Aberrantly Glycosylated Serum IgA1 Are Closely Associated with Pathologic Phenotypes of IgA Nephropathy.

Glycosylation and immunity

The Role of Immune Modulation in Pathogenesis of IgA Nephropathy

Systematic Review: Immunoglobulin G N-Glycans As Next-Generation Diagnostic Biomarkers for Common Chronic Diseases